Communiqués Natera, Inc.

Actions

NTRA

US6323071042

Installations et services en soins de santé

Temps réel estimé Cboe BZX Autres places de cotation 18:22:55 17/06/2026			Varia. 5j.	Varia. 1 janv.
229,46 ^USD	+4,25 %		+6,07 %	+0,24 %

13/06	Transcript : Natera, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 09:20 AM
12/06	Natera : RBC souligne la domination du groupe sur le marché " durable » et stratégique de la détection de la maladie résiduelle minimale	MT

Communiqués

10/06	Natera : Initial Statement of Beneficial Ownership (Form 3)	PU
04/06	Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer	BU
03/06	Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors	BU
29/05	Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma	BU
28/05	Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer	BU
27/05	Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology	AQ
26/05	Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology	BU
21/05	Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology	BU
21/05	Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World	BU
20/05	EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled	BU
15/05	Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)	BU
07/05	Natera: Q1 Earnings Snapshot	AQ
07/05	Natera : Q1 2026 Earnings Presentation	PU
07/05	Natera Reports First Quarter 2026 Financial Results	BU
30/04	Natera to Report its First Quarter Results on May 7, 2026	BU
22/04	Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT	BU
13/04	Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma	BU
09/04	Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents	BU
07/04	20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform	BU
31/03	SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery	BU
16/03	Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers	BU
13/03	Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis	AQ
12/03	Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis	BU
12/03	MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026	PR
04/03	Delhi High Court Dismisses Appeal Against Refusal Of Smelling Disease Patent	AQ